<b>Background</b><b>/Objectives:</b> Cyclic dinucleotide stimulator of interferon genes (STING) agonists have emerged as potential agents in cancer immunotherapy, but their clinical applications are limited by relatively poor pharmacokinetic properties. Here, STING1 is linked to cancer.